Sunday, April 12, 2026 – A new study reveals that popular diabetes and weight-loss drugs like Ozempic and Wegovy may not work as effectively for about 10% of people due to specific genetic variants. These individuals appear to have a puzzling condition called “GLP-1 resistance,” where their bodies produce higher levels of the hormone targeted by these drugs—but don’t respond to it properly.
Saturday, April 11, 2026 – Saturday, April 11 - More than a quarter of people with Type 2 diabetes take GLP-1 receptor agonists, but the popular diabetes drugs might not work as well for people who have certain genetic variants, according to a new study by Stanford Medicine scientists and their collaborators.
Friday, April 10, 2026 – Saturday, April 11 - (MedPage Today) -- GLP-1 receptor agonist use may be associated with a modest increase in erectile dysfunction (ED) risk in men with type 2 diabetes, a target trial emulation suggested.
Using U.S. electronic health record data, the incidence of...
Friday, April 10, 2026 – Saturday, April 11 - Here’s everything we know so far.
Friday, April 10, 2026 – Saturday, April 11 - New China-US biotech gets $54M: Vivatides Therapeutics raised the Series A for its preclinical-stage R&D in siRNA and antisense oligonucleotides aimed at reaching tissues beyond the liver. Vivatides’ investors include ...
Friday, April 10, 2026 – Friday, April 10 - By using AI to analyze more than 400,000 Reddit posts, Penn researchers have identified patient-reported symptoms associated with GLP-1s, the popular weight-loss and diabetes drugs semaglutide and tirzepatide, that may not be fully captured in clinical trials or regulatory documents.
Friday, April 10, 2026 – Friday, April 10 - → A decorated GLP-1 pioneer is retiring at Novo Nordisk.
Channeling Elvis Presley with a microphone emoji for good measure, Lotte Bjerre Knudsen said on LinkedIn that she “has left the ...
Friday, April 10, 2026 – Friday, April 10 - Research suggests GLP-1 drugs like Ozempic and Wegovy could double divorce risk, mirroring trends seen in bariatric surgery patients, experts say.
Thursday, April 9, 2026 – Friday, April 10 - Adults with overweight or obesity taking the new generation of weight loss drugs semaglutide and tirzepatide tend to eat significantly less, leaving them vulnerable to nutritional deficiencies, according to one of the first real-world studies to examine dietary behavior in people using glucagon-like peptide-1 receptor agonists and dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) dual agonists RAs (collectively referred to as GLP-1 RAs) with the help of an AI-powered nutritional tracking app.
Thursday, April 9, 2026 – Friday, April 10 - (MedPage Today) -- Integrating the most effective obesity treatments into cancer survivorship offers "an unprecedented opportunity" to improve long-term outcomes in cancer, including survival, a trio of obesity and oncology specialists argued in...